Sagimet Biosciences Inc (SGMT) concluded trading on Wednesday at a closing price of $4.08, with 20.27 million shares of worth about $82.69 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -28.30% during that period and on June 04, 2025 the price saw a gain of about 12.40%. Currently the company’s common shares owned by public are about 30.67M shares, out of which, 23.62M shares are available for trading.
Stock saw a price change of 20.00% in past 5 days and over the past one month there was a price change of 13.65%. Year-to-date (YTD), SGMT shares are showing a performance of -9.33% which decreased to -23.45% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.73 but also hit the highest price of $7.38 during that period. The average intraday trading volume for Sagimet Biosciences Inc shares is 507.32K. The stock is currently trading 20.23% above its 20-day simple moving average (SMA20), while that difference is up 32.26% for SMA50 and it goes to 1.19% higher than SMA200.
Sagimet Biosciences Inc (NASDAQ: SGMT) currently have 30.67M outstanding shares and institutions hold larger chunk of about 36.23% of that.
The stock has a current market capitalization of $125.15M and its 3Y-monthly beta is at 2.24. It has posted earnings per share of -$1.78 in the same period. It has Quick Ratio of 20.26 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SGMT, volatility over the week remained 5.72% while standing at 4.38% over the month.
Stock’s fiscal year EPS is expected to drop by -75.86% while it is estimated to decrease by -23.75% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Oppenheimer on December 06, 2024 offering an Outperform rating for the stock and assigned a target price of $30 to it. Coverage by UBS stated Sagimet Biosciences Inc (SGMT) stock as a Buy in their note to investors on November 12, 2024, suggesting a price target of $12 for the stock. On June 28, 2024, Goldman Downgrade their recommendations, while on May 02, 2024, H.C. Wainwright Initiated their ratings for the stock with a price target of $32. Stock get an Outperform rating from Leerink Partners on March 25, 2024.
